Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins

Molecular Cancer Therapeutics- United States

doi 10.1158/1535-7163.mct-15-0863

Full Text

Abstract

Available in

Date

Authors

Publisher

American Association for Cancer Research (AACR)

Related search

Targeting Mesothelin With Modified T Cells

Cancer Discovery
Oncology
2015English

Targeting a Membrane-Proximal Epitope on Mesothelin Increases the Tumoricidal Activity of a Bispecific Antibody Blocking CD47 on Mesothelin-Positive Tumors

mAbs
AllergyImmunology
2020English

Mesothelin-Mediated Targeting of Adenoviral Vectors for Ovarian Cancer Gene Therapy

Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2004English

545. Transductionally-Retargeted Infectivity Selective Oncolytic Adenovirus With Redesigned AB-Loop Targeting Cell Surface Mesothelin

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2012English

Mesothelin Targeted Cancer Immunotherapy

European Journal of Cancer
Cancer ResearchOncology
2008English

Combining Anti-Ctla4 With RG7787, an Immunotoxin Targeting Mesothelin, Promotes Tumor Eradication

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

The Hen Model of Human Ovarian Cancer Develops Anti-Mesothelin Autoantibodies in Response to Mesothelin Expressing Tumors

Journal of Ovarian Research
GynecologyOncologyObstetrics
2011English

A Recombinant Immunotoxin Against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity

Molecular Cancer Therapeutics
Cancer ResearchOncology
2012English

Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)

International Journal of Medical Sciences
Medicine
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy